A Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma

Patients will undergo stereotactic biopsy by craniotomy or burr hole.

Part A: Safusidenib Erbumine orally 250 mg BID for 28 days.

Surgery: Maximal safe resection, within 24 hours of last dose of Safusidenib Erbumine.

Part B: Safusidenib Erbumine orally 250 mg BID for 28 days for a minimum of 12, 28-day cycles subject to ongoing documented evidence of clinical benefit, until disease progression or unacceptable toxicity.